Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine

July 12, 2011 By Bio-Medicine.Org

OXFORD, England, July 12, 2011 /PRNewswire/ —

 

PharmaVentures Limited, experts in deals and alliances, are
pleased to announce that they have been engaged by Avexa Limited to
seek an out-licensing partner for apricitabine (ATC), a late-stage,
novel treatment for HIV infection.  The engagement will
utilise PharmaVentures’ global transactional expertise in the
healthcare and investment business sectors.

Dr Fintan Walton, CEO, PharmaVentures, commented, “We are
delighted to have been chosen by Avexa to assist in achieving its
business goal of maximising the return on investment in its
development compound apricitabine (ATC).  With 20 years’
experience of deals and alliances, PharmaVentures can provide Avexa
with immediate access to extensive licensing expertise and a
network of key decision makers in relevant companies.”

Iain Kirkwood, Chairman of Avexa, said, “The appointment of
PharmaVentures to work with and complement our management team is
the next logical step in the commercialisation of ATC following our
successful regulatory meeting with the FDA earlier this year.
PharmaVentures have an excellent reputation and track record in
this area.”

ATC is a novel nucleoside, a class of compound known to be a
vital component of anti-HIV therapy.  ATC offers a new
extension to existing therapies in the treatment of drug-resistant
HIV, especially for those patients with limited remaining
therapeutic options.

PharmaVentures is a leading life sciences transaction advisory
firm with strong capabilities in finding and evaluating
opportunities and negotiating deals.  The licensing team has
an established track record in generating outstanding value for
PharmaVentures’ clients and has assisted in over 100 transactions
in the past 20 years.  

About PharmaVentures Limited

PharmaVentures Limited (http://www.pharmaventures.com)
is a leading inte

‘/>”/>

SOURCE

Related Articles Read More >

Engineer inspecting artificial hip joint parts in quality control department in orthopaedic factory
Deburring and finishing for beautiful, functional medical devices
A Medtronic HVAD pump opened up to show the inner workings
FDA designates new Medtronic HVAD pump implant recall as Class I
Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age

DeviceTalks Weekly.

June 24, 2022
How innovative design, commercial strategy is building Cala Trio’s bioelectronic medicine market
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech